💊Executive Order for Regulatory Relief in Pharmaceutical Production
Regulatory Relief To Promote Domestic Production of Critical Medicines
Summary
Executive Order 14293 emphasizes the necessity of regulatory relief to support the domestic production of essential medicines. It outlines measures to streamline the review processes by key agencies like the FDA and EPA, aiming to eliminate barriers to pharmaceutical manufacturing. The order highlights a strategic initiative to secure a resilient domestic pharmaceutical supply chain and enhance national security.
Agencies
- Executive Office of the President
Business Impact
$$$ - High
The executive order aims to streamline and expedite regulatory processes for the domestic production of pharmaceutical products, potentially easing compliance for businesses in the sector and fostering investment. Sections outline actions to eliminate redundancies and accelerate the creation of manufacturing facilities, which are vital for businesses looking to operate effectively domestically.